Get access

Ribavirin therapeutic drug monitoring: why, when and how?

Authors

  • Françoise Stanke-Labesque,

    1. INSERM ERI17; Univ Grenoble; CHU Grenoble, Service de Pharmacologie-toxicologie, France
    2. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    3. Therapeutic drug monitoring group of the French society of pharmacology and therapeutic
    Search for more papers by this author
  • Véronique Loustaud-Ratti,

    1. CHU Limoges, Hepatology Federation, Limoges, France
    2. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    Search for more papers by this author
  • Gérard Babany,

    1. Roche, Neuilly sur Seine, France
    2. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    Search for more papers by this author
  • Marie-Claude Gagnieu,

    1. Hospices Civils de Lyon, Laboratoire de pharmacologie, Hôpital Edouard Herriot, Lyon, France
    2. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    3. Therapeutic drug monitoring group of the French society of pharmacology and therapeutic
    Search for more papers by this author
  • Pierre Marquet,

    1. INSERM U850; Univ Limoges; CHU Limoges, Service de Pharmacologie et Toxicologie, Pharmacovigilance, France
    2. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    3. Therapeutic drug monitoring group of the French society of pharmacology and therapeutic
    Search for more papers by this author
  • The French Ribavirin Group OPTIRIB

    1. OPTIRIB Group: Victor de Ledinghen (Bordeaux); Françoise Stanke-Labesque, Jean-Pierre Zarski (Grenoble); Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet (Limoges); Marie-Claude Gagnieu, Marianne Maynard, Christian Trépo (Lyon); Marc Bourlière, Caroline Solas (Marseille); Gérard Babany, Monelle Muntlak (Roche)
    Search for more papers by this author

Correspondence and reprints: fstanke@chu-grenoble.fr

Abstract

Recent studies suggest the potential interest of ribavirin therapeutic drug monitoring to improve sustain virological response rate in hepatitis C virus-infected patients. The present review details the pharmacokinetic properties of ribavirin, suggesting that it may be a good candidate for therapeutic drug monitoring, the different possible strategies and the analytical methods that could be employed.

Ancillary